Valuation : Genmab A/S

Market Cap 129B 20.11B 17.29B 16.27B 14.84B 27.7B 1,906B 27.85B 193B 74.57B 974B 75.51B 73.86B 3,101B P/E 2026 *
27.4x
P/E 2027 * 19.3x
Enterprise Value 149B 23.12B 19.88B 18.7B 17.06B 31.84B 2,192B 32.01B 222B 85.72B 1,120B 86.8B 84.91B 3,565B EV / Sales 2026 *
5.13x
EV / Sales 2027 * 4.17x
Free-Float
94.3%
Yield 2026 *
-
Yield 2027 * -
1 day+1.12%
1 week+0.84%
Current month+2.03%
1 month+8.30%
3 months+34.39%
6 months+25.25%
Current year+6.81%
1 week 2,136
Extreme 2136
2,232
1 month 1,958.5
Extreme 1958.5
2,232
Current year 1,512
Extreme 1512
2,257
1 year 1,512
Extreme 1512
2,257
3 years 1,157
Extreme 1157
2,710
5 years 1,157
Extreme 1157
3,327
10 years 786.2
Extreme 786.2
3,327
Manager TitleAgeSince
Chief Executive Officer 65 2010-05-31
Director of Finance/CFO 48 2020-02-29
Chief Tech/Sci/R&D Officer - 2024-08-15
Director TitleAgeSince
Director/Board Member 75 2003-10-31
Director/Board Member 58 2014-12-31
Director/Board Member 75 2014-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
12/1/25 Exercice

Director

189 0.0003%
12/1/25 Exercice

Director

189 0.0003%
12/1/25 Exercice

Director

283 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
+1.12%+0.84%+24.50%-17.84% 20.11B
+2.02%+1.26%+41.37%+105.18% 69.19B
-0.41%-2.30%+33.53%+78.63% 62.97B
-1.11%+2.78%-14.86%+375.59% 27.27B
-4.92%-3.22%-3.90%-17.87% 24.78B
+0.45%+0.57%+31.49%+15.97% 25.8B
+6.04%+7.25%+233.25%+383.12% 18.47B
+0.33%-0.69%-6.48%+526.89% 14.88B
-2.27%+1.37%+53.01%+160.83% 14.29B
-1.85%+22.03%-11.13%+1,022.08% 13.79B
Average -0.06%+2.87%+38.08%+263.26% 29.15B
Weighted average by Cap. +0.19%+1.15%+36.33%+183.11%

Financials

2026 *2027 *
Net sales 28.94B 4.5B 3.87B 3.64B 3.32B 6.2B 427B 6.23B 43.15B 16.69B 218B 16.91B 16.54B 694B 33.7B 5.24B 4.51B 4.24B 3.87B 7.22B 497B 7.26B 50.25B 19.44B 254B 19.69B 19.26B 809B
Net income 4.92B 765M 658M 619M 565M 1.05B 72.5B 1.06B 7.33B 2.84B 37.06B 2.87B 2.81B 118B 7.1B 1.1B 949M 893M 815M 1.52B 105B 1.53B 10.58B 4.09B 53.51B 4.15B 4.06B 170B
Net Debt 19.32B 3.01B 2.59B 2.43B 2.22B 4.14B 285B 4.16B 28.82B 11.15B 146B 11.29B 11.04B 464B 11.25B 1.75B 1.5B 1.42B 1.29B 2.41B 166B 2.42B 16.77B 6.49B 84.8B 6.57B 6.43B 270B
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,119
Date Price Change Volume
26-09-08 DKK 2,165.00 +1.12% 61,723
26-09-07 DKK 2,141.00 -1.11% 38,161
26-09-04 DKK 2,165.00 -1.46% 85,258
26-09-03 DKK 2,197.00 +1.01% 95,427
26-09-02 DKK 2,175.00 +1.30% 108,985
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
2,165.00DKK
Average target price
2,453.79DKK
Spread / Average Target
+13.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GMAB Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!